nuclear receptor raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-01-17 and is reviewed periodically as new material appears.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
| Property | Value | Notes |
|---|---|---|
| Solubility | Soluble in dimethyl sulfoxide and some organic solvents; practically insoluble in water | Solvent choice affects laboratory handling |
| Typical storage | -20 °C, desiccated, protected from light | Common condition for research samples |
| Analytical method | Liquid chromatography–tandem mass spectrometry (LC-MS/MS) | Used for identification and quantification in biological or product samples |
| Common synonyms | GW501516, GW-501516, GSK-516, Endurobol | Names found in research and anti-doping literature |
| Regulatory status | Unapproved therapeutic; prohibited in competitive sport | Status can vary by country and context |
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
Some enzymes need to go through a maturation process to be activated. A precursor (inactive state, better known as zymogen) is first synthesized, and then, by cutting some specific peptide bonds (enzymatic catalysis by hydrolytic selective split), its 3D conformation is highly modified into a catalytic functional status, obtaining the active enzyme. Proteolysis is irreversible and normally a non-specific process. The same activator can modulate different regulatory enzymes : once trypsin is activated, it activates many other hydrolytic enzymes. Proteolysis can also be fast and simple so the hydrolysis of a single peptide bond can be enough to change the conformation of the protein and build an active zone, allowing the interaction between the enzyme and the substrate, for instance, chymotrypsin activation (as it can be seen in the images). Many different types of proteins with different roles in metabolism are activated by proteolysis for big reasons:
== External links == TMA-2 - Isomer Design TMA-2 - PsychonautWiki TMA-2 - Erowid TMA-2 - PiHKAL - Erowid TMA-2 - PiHKAL - Isomer Design TMA-2: An Amphetamine Compound With Unique Sedative Properties - Tripsitter
The Hofmeister series or lyotropic series is a classification of ions in order of their lyotrophic properties, which is the ability to salt out or salt in proteins. The effects of these changes were first worked out by Franz Hofmeister, who studied the effects of cations and anions on the solubility of proteins.
=== Scleroderma === Scleroderma, also known as systemic sclerosis, is a chronic systemic autoimmune disease characterised by hardening (sclero) of the skin (derma) that affects internal organs in its more severe forms. mTOR plays a role in fibrotic diseases and autoimmunity, and blockade of the mTORC pathway is under investigation as a treatment for scleroderma.
The Don Cossacks flag 3:4 was inaugurated during the Don Cossacks assembly in Novocherkassk, Don Republic, on 4 May 1918 under chiefing of Ataman Pyotr Krasnov. The flag has three colours: blue, yellow, and red. The flag is similar to that of the Ukrainian State, also established in 1918, which the Don Republic bordered to its west.
Sources: en.wikipedia.org
Further purification of the protein from rat livers and kidneys in 1980 by Polish biochemists led by Andrzej J. Żelazowski and Jadwiga A. Szymańska indicated that the protein exists in distinct types (isoforms), each specific for cadmium, copper and mercury. These proteins were later named isoforms of type 1 and 2 (MT1 and MT2). In 1991, a team of Japanese neuroscientists found a different metallothionein in human brain that acted as growth inhibitor and linked to Alzheimer's disease. The protein became MT3. In 1994, a team led by Richard D. Palmiter of the University of Washington discovered the fourth type, MT4, from the epithelial cells of mouse and humans. The formal classification was introduced by Pierre-Alain Binz and Kägi in 1999. Due to their obscure nature and diversity, the exact biological functions of metallothioneins were difficult to study and became established only by the mid-1990s. As Vallee later remarked, it took "40 years of frustrating efforts" to understand that the proteins are responsible for several fundamental cellular activities including zinc-dependent gene activation, growth inhibition of neurones, apoptosis and regulation of oxidative stress.
== FPR3 function == The overall function of FPR3 is quite unclear. Compared to FPR1 and FPR2, FPR3 is highly phosphorylated (a signal for receptor inactivation and internalization) and more localized to small intracellular vesicles. This suggests that FPR3 rapidly internalizes after binding its ligands and thereby may serve as a "decoy" receptor to reduce the binding of its ligands to FRP1 and FRP2 receptors.
There is one atrium (which receives blood) and one ventricle (which expels blood) for each circulation, with a total of four chambers: left atrium, left ventricle, right atrium and right ventricle. Chambers of the heart are separated by the atrioventricular valves, which include the tricuspid valve on the right and the mitral valve on the left. The ventricles are separated from the large arteries via the semilunar valves. The heart is lined by a double-layered sac known as the pericardium. Further circulatory routes include the coronary circulation to the heart itself, the cerebral circulation to the brain, renal circulation to the kidneys, and bronchial circulation to the bronchi in the lungs.
Krebiozen (aka Carcalon, creatine, substance X, or drug X) is a disproven alternative cancer treatment. While the substance has been marketed as a cure for cancer, originally sold for thousands of dollars per dose in the 1950s and early '60s, Krebiozen is not known to possess any therapeutic value. Attempts to analyze this patent medicine have shown that Krebiozen consists only of the amino acid creatine dissolved in mineral oil, and some samples sold as Krebiozen consist solely of mineral oil with no other discernible ingredients. The American Cancer Society (ACS) states: "Available scientific evidence does not support claims that Krebiozen is effective in treating cancer or any other disease." ACS did not have data on safety but noted that "creatine supplements have been linked with some side effects."
The idea of "no independence before majority rule", commonly abbreviated to "NIBMAR", gained considerable ground in British political circles. When Huggins (who had been recently ennobled as Lord Malvern) asked Britain to make the Federation a dominion in 1956, he was rebuffed. The opposition Dominion Party responded by repeatedly calling for a Federal unilateral declaration of independence (UDI) over the next few years. Following Lord Malvern's retirement in late 1956, his successor Sir Roy Welensky pondered such a move on at least three occasions. Attempting to advance the case for Southern Rhodesian independence, particularly in the event of Federal dissolution, the Southern Rhodesian Prime Minister Sir Edgar Whitehead brokered the 1961 constitution with Britain, which he thought would remove all British powers of reservation over Southern Rhodesian bills and acts, and put the country on the brink of full sovereignty. Despite its containing no independence guarantees, Whitehead, Welensky and other proponents of this constitution presented it to the Southern Rhodesian electorate as the "independence constitution" under which Southern Rhodesia would become a dominion on a par with Australia, Canada and New Zealand if the Federation dissolved. White dissenters included Ian Smith, MP for Gwanda and Chief Whip for the governing United Federal Party (UFP) in the Federal Assembly, who took exception to the constitution's omission of an explicit promise of Southern Rhodesian independence in the event of Federal dissolution, and ultimately resigned his post in protest.
Sources: en.wikipedia.org
It binds and activates PPARδ, a nuclear receptor that influences gene expression related to fatty acid metabolism and energy balance. This mechanism has been studied mainly in animals and cell models, not established as a safe human therapy.
No. It is not an anabolic-androgenic steroid; it is a synthetic PPARδ agonist. Because it is banned in sport, it is sometimes grouped with doping agents even though its chemical class differs from steroids.
Human data are limited and development was discontinued, so major effects and long-term risks are not well characterized. Some early studies examined metabolic markers, but they do not provide a basis for unsupervised use.
Cardarine is a common name for GW501516, a synthetic PPARδ agonist developed for research. It has not been approved as a medication in any country. It is classified as an unapproved drug and a prohibited substance in sport.